Sector News

Study suggests AI could provide second reading of mammograms

September 15, 2023
Life sciences

AI solutions have proliferated in medical imaging, where ample data is available to train algorithms to detect cancer, stroke and other serious conditions. Lunit’s Insight MMG solution has received 510(k) clearance from the Food and Drug Administration and a CE mark in Europe. Other competitors in the space include iCAD and ScreenPoint Medical.

The prospective study included more than 58,000 women who had regular mammography screenings at Capio Sankt Göran Hospital in Stockholm. Consistent with usual care at the hospital, if any of the readers reported abnormal findings, two radiologists would have a consensus discussion before deciding whether to send patients for additional imaging.

The study found that readings from a radiologist and an AI reader resulted in a 4% increase in screen-detected cancers, or about 11 more cases, compared to two radiologists. However, the AI-radiologist duo also caused a 21% increase in the number of examinations with an abnormal interpretation, resulting in more consensus discussions. This did not translate into an increased recall rate for additional imaging. READ MORE

by Elise Reuter


comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach